Design of ^<99m>Tc-labled compound for diagnosis of metastatic tumor in bone
| Project/Area Number |
21791172
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
上原 知也 Chiba University, 大学院・薬学研究院, 講師 (10323403)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 放射性医薬品 / D-penicillamine / オリゴアスパラギン酸 / SPECT |
|---|
| Research Abstract |
Increased permeability of blood vessels in diseased bone suggested that ^<99m>Tc-labeled compound of higher molecular size and hydroxyapatite binding would be useful to detect the diseased bone. Since ^<99m>Tc-labeled oligo-aspartic acid showed higher molecular size and higher hydroxyapatite binding than those of ^<99m>Tc-methylenediphosphonate (^<99m>Tc-MDP), to evaluate the molecular design of ^<999m>Tc-labeled oligo-aspartic acid, the accumulation of ^<99m>Tc-labeled oligo-aspartic acid in bone metastatic tumor of rat was compared with ^<99m>Tc-MDP. The tumor to normal region ratios of ^<99m>Tc-labeled oligo-aspartic acids were higher than those of ^<99m>Tc-MDP. These results suggested that the present molecular design would be useful to image bone metastatic tumor.
|
Report
(3 results)
Research Products
(2 results)
